Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 92% Improvement Relative Risk Oxygen therapy 94% c19early.org/r Faraone et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experience
Faraone et al., Research Square, doi:10.21203/rs.3.rs-1170976/v1 (Preprint)
Faraone et al., REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early.., Research Square, doi:10.21203/rs.3.rs-1170976/v1 (Preprint)
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 34 patients with hospital-acquired COVID-19, showing lower mortality and oxygen requirements with early casirivimab/imdevimab treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of death, 92.2% lower, RR 0.08, p = 0.03, treatment 0 of 11 (0.0%), control 8 of 23 (34.8%), NNT 2.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of oxygen therapy, 94.5% lower, RR 0.06, p = 0.02, treatment 0 of 11 (0.0%), control 15 of 23 (65.2%), NNT 1.5, odds ratio converted to relative risk, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Faraone et al., 5 May 2022, retrospective, Italy, preprint, 12 authors, study period 25 October, 2020 - 30 April, 2021, average treatment delay 2.3 days.
Contact: antfaraone@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experience Antonio Faraone (  antfaraone@gmail.com ) Ospedale San Giovanni di Dio https://orcid.org/0000-0001-6095-8403 Francesca Fabbrizzi Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Tommaso Picchioni Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Elena Lovicu Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Lorenzo Tofani Department of Statistics, Computer Science, Applications, University of Florence, Florence Giulia Scocchera Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Aldo Lo Forte Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Andrea Crociani Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Paolo Carrai Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Serena Sbaragli Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Michael Bettucchi Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Alberto Fortini Department of Internal Medicine, San Giovanni di Dio Hospital, Florence Research Article Keywords: casirivimab/imdevimab, COVID-19, hospital-acquired, inpatient, monoclonal antibody, REGENCOV. Page 1/17 Posted Date: May 5th, 2022 DOI: https://doi.org/10.21203/rs.3.rs-1170976/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/17 Abstract Inpatients with hospital-acquired (HA) COVID-19 have mortality rates above 30%. Subjects with early diagnosis of COVID-19 and risk factors for disease progression are suitable for treatment with anti-SARSCoV-2 neutralizing monoclonal antibodies (mAbs). We retrospectively assessed the outcome of a cohort of hospitalized patients with laboratory confirmed SARS-CoV-2 nosocomial infection who were admitted to the COVID-19 general ward of an acute-care Italian hospital between October 25, 2020 and April 30, 2021. Patients receiving the REGEN-COV mAb cocktail (casirivimab/imdevimab) were compared with those receiving standard care. Of 34 patients, 11 (mean age, 73.1; 9 males) underwent treatment with REGEN-COV and 23 received standard care. The 2 study groups were well balanced regarding age, sex, comorbidities, acute illness severity at diagnosis of SARS-CoV-2 infection, and all participants had at least 2 risk factors for disease progression. Five of 11 patients in the REGEN-COV group and 16 of 23 in the standard care group were asymptomatic at diagnosis; the remaining had symptoms of mild COVID-19. All patients received REGENCOV within 3 days of infection confirmation. Treatment with REGEN-COV was inversely associated with oxygen requirement for COVID-19 during hospital stay (OR 0.02, CI 0–0.52, p=0.0174). No 28-day deaths were registered in the REGEN-COV group, compared to 8 (34.8%) in the standard care group (p=0.0339). Kaplan-Meier analysis confirmed the survival advantage of REGEN-COV group (log-rank p=0.00324). No serious adverse events related to REGEN-COV administration were recorded. Based on these findings, REGEN-COV appears safe and might prevent disease progression in high-risk inpatients with early diagnosis of HA-COVID-19.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit